AMR Action Fund CEO Henry Skinner, PhD, MBE, provides insights around the legislation including its implementation challenges which may be slowing its path to passage despite bipartisan support in Congress as well as growing recognition of the global antimicrobial resistance crisis.
Lily Li, MD, PhD, MBA, discusses factors for increasing incidence rates including low awareness, asymptomatic spread, and gaps in testing and care access, and strategies to increase early. She also provides a brief overview for some of the testing options for the infectious disease.
In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones.
In the second episode of this short series, Akhila Kosaraju, MD, talks about how Phare Bio and Basilea Pharmaceuticals are partnering to develop antimicrobials taking them from AI molecules to clinical trials.
A new study shows that strain-level surveillance of Staphylococcus aureus in NICUs can identify hidden transmission pathways and enable targeted interventions to reduce serious infections in vulnerable newborns.
Early adoption of genomic surveillance and rigorous infection prevention protocols has enabled one health system to prevent in-hospital outbreaks of Candida auris despite rising cases nationwide. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) provides insights on how his institution is handling testing for this problematic fungal infection.
Patricia A Stinchfield, RN, MS, CPNP, discusses her medical experience caring for patients with it, and what fellow clinicians and the general public should know about less-discussed details and potential complications.
Chloe Orkin, MD, MSc, discusses the takeaways of the ARTISTRY-1 phase 3 study, including its efficacy and safety profile and the potential benefits of a single-tablet regimen in this patient population.
IDSA’s Amanda Jezek provides the latest update on the legislative bill, including some of its features, its methodology for assigning antimicrobials to the subscription model, and how anyone can advocate for the bill with Congress.
In the second installment of a 2-part interview, Jacinda Abdul-Mutakabbir, PharmD, MPH, offers some novel findings around UTI treatment failure associated with levels of education and insurance payers.
Jacinda Abdul-Mutakabbir, PharmD, MPH, discusses her research in this area and how to potentially mitigate these treatment disparities.
Emory’s Jill Morgan, RN, BSN, discusses what they do after removal of personal protective equipment (PPE) and if a provider has experienced a potential exposure to a high-consequence infectious disease.
Sharon Carrasco DNP, APRN, ACNS-BC, ANP-C, CEN, FAEN, FAAN, FNAP, discusses her approach to training for these care scenarios.
Early international experience and evolving real-world data indicate that the new MBL-targeting regimen shows strong potential for US clinicians, despite expected resistance patterns and still-developing evidence.
Clinicians should view the open-label data as promising but preliminary, with post-marketing evidence expected to play a critical role in defining its place in guidelines for treating MBL-producing, multidrug-resistant infections.
Emory's Gavin Harris, MD, talks about taking care of patients with high-consequence infectious diseases, and considerations for not only their care, but their families. He also discusses working with other healthcare facilities around COVID-19 care and educating them through Emory's ECHO program on new and existing threats.
Aztreonam-avibactam achieved noninferior clinical cure rates and a comparable safety profile to meropenem/colistin, even amid a high proportion of carbapenemase-producing pathogens.
Margaret Aldrich, MD, provides insight around this concept, addressing stewardship within this patient population, and how their institution’s collaborative work environment helps all of the department’s clinicians.
Infectious disease pediatrician Sharon Nachman, MD, talks about how the new recommendations will defer immunization, leading to a whole host of issues and negative impacts on long-term public health.
NYU Langone’s Angelica Cifuentes Kottkamp, MD, continues our Media Day discussion around these illnesses and how in New York City, clinicians need to be prepared to decipher in differential diagnosis for these potential diseases.
In episode 2 of our Media Day series with NYU Langone, Angelica Cifuentes Kottkamp, MD, discusses its vaccine center and their work around COVID-19 vaccines, as well as the importance of achieving diversity in clinical trials.
Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, discusses the changes in the new vaccine recommendations and what potential serious consequences may be seen as a result.
Joshua Rosenberg, MD, continues the discussion on the REVISIT study, which showed comparable—or lower—28-day mortality rates than meropenem/colistin despite treating a higher proportion of patients with metallo-β-lactamase–producing pathogens.
Angelica Cifuentes Kottkamp, MD, discusses how its location, breadth of experience, and opportunities afford clinicians the ability to see and treat a wide berth of diseases and infections.
Joshua Rosenberg, MD, discuses the differences in clinical trials that enroll both intra-abdominal infection patients and those with hospital- or ventilator-associated pneumonia face major complexity because these two groups differ widely in baseline severity, mortality risk, and expected treatment outcomes
A novel pairing of aztreonam and avibactam offers a long-needed solution to combat highly drug-resistant gram-negative bacteria, particularly those producing difficult-to-treat metallo-β-lactamases.
Shionogi has been identifying in vitro activity using its antibiotic, cefiderocol, against Gram-negative clinical isolates such as carbapenem-resistant Enterobacterales (CRE). Christine Slover, PharmD, offers some insights on the company’s analysis.
Timothy Jenkins, MD, talks about how these important tests are being overly used for respiratory and gastrointestinal presentations and strategies his institution, Denver Health, is employing to reduce testing to save costs and still continuing to achieve optimal treatment outcomes.
Kaylee Caniff, PharmD, BCIDP, provides insights on a study looking at how urban and rural healthcare settings differ in terms of prescribing.
Nathan Shively, MD, talks about the increase of this antibiotic at his institution over the last several years for a variety of infections, particularly osteomyelitis. He also provides insights about dalbavancin's profile including its efficacy and adverse effects.
